Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

As part of the deal, the patients' attorney Jeremy Knowles said Aurora IV & Wellness will surrender its license and will not ...

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

New Investigator Sponsored Data Suggest Trilaciclib May Mitigate Chemotherapy-Induced TP53-Mutant Clonal Hematopoiesis. EINPresswire/ -- Pharmacosmos Therapeutics Inc. today announced the presentation ...

Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company's intravenous (IV) Deciparticle(TM) formulation of everolimus, substantially ...

Comedian Park Na-rae, 40 years old, has faced allegations of receiving illegal medical treatments, following prior ...

In a dvm360 interview, Christopher Lee, DVM, MPH, DACVPM, DACVM (Parasitology); Cert: FFC, CFV, RECOVER-ALS, recommends prioritizing epinephrine and species-specific administration to improve patient ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Comedian Park Na-rae, who has faced allegations of power abuse against her manager and embezzlement suspicions, is now under scrutiny for allegedly receiving unauthorized medical treatment. The ...

The University of Wisconsin-Madison partnered with biotechnology company TAE Life Sciences to launch the first clinical site for Neutron Capture Therapy (NCT) in the United States, positioning the ...

BARYTHRAX inj. is the first anthrax vaccine globally to be developed using recombinant protein technology. Unlike ...

Gavin Newsom has epically trolled Donald Trump once again. This time, the California governor mocked the recently added ...